These advances have facilitated the exploration of multitarget hybrid structures, which not only inhibit AChE but also possess antioxidant or anti-inflammatory properties, opening new therapeutic avenues for neurodegenerative diseases. This evidence concerns the gene ACHE and neurodegenerative disease.